Ophirex, Inc.
Corte Madera, CA
- UEI
- W452WY5E2JQ9
- CAGE
- 7JTR0
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Other
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 5643 Paradise Dr # 2, Corte Madera, CA 94925, USA
- Website
- ophirex.com
- Founded
- 2015
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $10,815,358 |
| FY2025 | $18,539,085 |
| FY2024 | $4,530,514 |
| FY2023 | $6,516,879 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Defense Health Agency | $10,815,358 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Development of intravenous varespladib, a phospholipase A2 inhibitor, for the treatment of snakebite envenoming - 1… | FDA Office of Acquisition and Grant Services | $5,116,580 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Rare Disease Therapeutics, Inc. | Franklin, TN | 424210 Drugs and Druggists' Sundries Merchant Wholesalers |
| Centivax, Inc. | South San Francisco, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Ophirex, Inc. is a for-profit small business located in Corte Madera, California, focused on developing medical treatments for snakebite envenomation. The company operates as a public benefit corporation with a mission to reduce death and disability from snakebite through innovative pharmaceutical research and development. Ophirex specializes in developing advanced pharmaceutical interventions, particularly focusing on a novel treatment called varespladib, which is designed to inhibit snake venom toxins and provide more effective treatment for snakebite victims.
The federal contract awards Ophirex has received are exclusively through the Small Business Innovation Research (SBIR) program, primarily from the Defense Health Agency (DHA) and the Department of the Army Medical Command. These contracts, totaling approximately $84.7 million, are specifically targeted at developing a broad-spectrum snakebite antidote with both oral and intravenous formulations. The contracts are structured as definitive and other transaction agreements, with total small business set-aside designations. The research focuses on developing varespladib, a phospholipase A2 inhibitor that can potentially improve recovery time and reduce complications from snakebite envenomation, with contract work performed in Corte Madera, California and completion dates ranging from December 2025 to May 2028.
Ophirex has received a federal grant from the FDA's Office of Medical Products and Tobacco to support the development of an intravenous varespladib formulation for snakebite envenoming treatment. The grant, awarded on September 15, 2023, with a completion date of August 31, 2026, supports a Phase IIB double-blind randomized controlled trial. The grant's project summary indicates the research aims to demonstrate the efficacy of varespladib in treating snakebite, with a focus on inhibiting snake venom secretory phospholipase A2 (sPLA2), which is found in approximately 95% of medically important venomous snakes. The research seeks to address the limitations of current antivenom treatments by developing a more comprehensive and effective intervention for snakebite victims.
Quick answers
Is Ophirex, Inc. registered in SAM.gov?
Yes. Ophirex, Inc.'s SAM.gov registration is active through January 22, 2027.
What is Ophirex, Inc.'s CAGE code?
Ophirex, Inc.'s CAGE code is 7JTR0, and its Unique Entity ID (UEI) is W452WY5E2JQ9.
How much has Ophirex, Inc. received in federal contracts?
Federal contracts obligated $18,539,085 to Ophirex, Inc. in fiscal year 2025 and $40,401,836 in fiscal years 2023 through 2027.
How does Ophirex, Inc. rank among federal contractors?
Ophirex, Inc. ranked #10 in PSC AN12, #46 in PSC AN and #85 at the Defense Health Agency in FY2025.
What is Ophirex, Inc.'s most recent federal award?
Ophirex, Inc.'s most recent federal contract award is DHA phase III small business innovation research prototype other transaction agreement for project titled, "broad… (HT94252590011), from Defense Health Agency, on May 5, 2025.
On GovTribe
See Ophirex, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors